NCT03228667 2026-01-14QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsImmunityBio, Inc.Phase 2 Active not recruiting40 enrolled
NCT04068831 2024-12-27Talazoparib and Avelumab in Participants With Metastatic Renal Cell CarcinomaMemorial Sloan Kettering Cancer CenterPhase 2 Completed18 enrolled 9 charts
NCT05429866 2023-03-08Immunological Variables Associated to ICI Toxicity in Cancer PatientsJules Bordet InstitutePhase 2 Unknown441 enrolled
NCT04150562 2022-05-17Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal CarcinomaNational Institutes of Health Clinical Center (CC)Phase 2 Terminated2 enrolled 13 charts
NCT03035630 2022-02-15Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell CarcinomaHoosier Cancer Research NetworkPhase 2 Withdrawn
NCT03341845 2018-05-21Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCCThe Netherlands Cancer InstitutePhase 2 Unknown40 enrolled